Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Not Yet Recruiting NCT07850635

A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Conditions: Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

Sex: All

Ages: 0 Months – 21 Months

Healthy volunteers: No

Phase: PHASE1

Enrollment: 6

Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Location: Research Site Darmstadt

Summary

The purpose of this study is to determine the safety, pharmacokinetic (PK), and tolerability of multiple treatment cycles of oral mirdametinib in infants and toddlers (0 to less than \[\

Eligibility Criteria

Inclusion Criteria: 1. Age 1.1 Cohort 1: greater than (\>) 12 to less than or equal to (\

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07850635). StuddyBuddy aggregates publicly available trial information.